Results 1 to 10 of about 120,973 (392)

Azathioprine in Rheumatoid Arthritis [PDF]

open access: greenBMJ, 1969
The ability of azathioprine to reduce the corticosteroid requirements of patients with severe rheumatoid arthritis was tested under double-blind conditions against placebo. After 12 months a significant mean dose reduction of 36% was achieved without undue side-effects.
Michael Mason   +5 more
openaire   +4 more sources

Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. [PDF]

open access: yesPLoS ONE, 2014
For almost three decades in many countries azathioprine has been used to treat relapsing-remitting multiple sclerosis. However its efficacy was usually considered marginal and following approval of β interferons for this indication it was no longer ...
Luca Massacesi   +10 more
doaj   +2 more sources

Severe distributive shock, neutrophilic dermatosis, and ST-elevation myocardial infarction in the setting of azathioprine hypersensitivity syndrome [PDF]

open access: yesAllergy, Asthma & Clinical Immunology
Background Azathioprine is a purine synthesis inhibitor used as an immunosuppressive therapy for many immune-mediated diseases. Azathioprine hypersensitivity reaction is a rare, life-threatening adverse reaction characterized by a range of multisystem ...
Samuel Su   +5 more
doaj   +2 more sources

Azathioprine in Psoriasis [PDF]

open access: bronzeProceedings of the Royal Society of Medicine, 1973
D.D. MUNRO
openaire   +4 more sources

A Case of Azathioprine Induced Severe Myelosuppression and Alopecia Totalis in IgA Nephropathy [PDF]

open access: yesChildhood Kidney Diseases, 2017
Azathioprine is commonly used as immunosuppressive therapy for various inflammatory diseases including chronic glomerulonephritis. Myelosuppression is a common side effect of azathioprine, resulting in the need for dose reduction.
Jae Choon Kim   +6 more
doaj   +1 more source

Sensing Methods of Immunosuppressant Drugs: Calcineurin Inhibitors and Purine Synthesis Inhibitor Agents [PDF]

open access: yesImmunoAnalysis, 2021
Today, immunosuppression is associated as a necessary protocol in renal posttransplantation follow-up to improve both patient and graft survival rates.
Zahra Golsanamlou   +2 more
doaj   +1 more source

Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura

open access: yesJournal of Nepal Medical Association, 2016
Introduction: Immune thrombocytopenic purpura remains common blood disease in Nepal. Azathioprine is an oral immunosupressive medicine which has been used widely in various autoimmune disease and solid organ transplant patients. It is inexpensive, easily
Bishesh Sharma Poudyal   +5 more
doaj   +3 more sources

Use of thiopurines in inflammatory bowel disease: an update [PDF]

open access: yesIntestinal Research, 2022
Inflammatory bowel disease (IBD), once considered a disease of the Western hemisphere, has emerged as a global disease. As the disease prevalence is on a steady rise, management of IBD has come under the spotlight.
Arshdeep Singh   +25 more
doaj   +1 more source

Predicted expression of genes involved in the thiopurine metabolic pathway and azathioprine discontinuation due to myelotoxicity

open access: yesClinical and Translational Science, 2022
TPMT and NUDT15 variants explain less than 25% of azathioprine‐associated myelotoxicity. There are 25 additional genes in the thiopurine pathway that could also contribute to azathioprine myelotoxicity.
Laura L. Daniel   +17 more
doaj   +1 more source

Optical Coherence Tomography Reveals Longitudinal Changes in Retinal Damage Under Different Treatments for Neuromyelitis Optica Spectrum Disorder

open access: yesFrontiers in Neurology, 2021
Background: Progressive retinal neuroaxonal damage after acute optic neuritis may occur in neuromyelitis optica spectrum disorder (NMOSD). However, it is unclear if treatments used to prevent attacks influence neurodegeneration.Objectives: We aimed to ...
Pei Zeng   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy